Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Sheu JR, Hsiao G, Shen MY, Fong TH, Chen YW, Lin CH, Chou DS
------>authors3_c=None
------>paper_class1=1
------>Impact_Factor=None
------>paper_class3=2
------>paper_class2=1
------>vol=119
------>confirm_bywho=sheujr
------>insert_bywho=sheujr
------>Jurnal_Rank=None
------>authors4_c=None
------>comm_author=
------>patent_EDate=None
------>authors5_c=None
------>publish_day=None
------>paper_class2Letter=None
------>page2=1041
------>medlineContent=
------>unit=E0200
------>insert_date=20030324
------>iam=1
------>update_date=
------>author=???
------>change_event=5
------>ISSN=None
------>authors_c=None
------>score=500
------>journal_name=Br. J. Haematol.
------>paper_name=Mechanisms involved in the antiplatelet activity of magnesium in human platelets.
------>confirm_date=20030421
------>tch_id=082005
------>pmid=12472585
------>page1=1033
------>fullAbstract=In this study, magnesium sulphate dose-dependently (0.6-3.0 mmol/l) inhibited platelet aggregation in human platelets stimulated by agonists. Furthermore, magnesium sulphate (3.0 mmol/l) markedly interfered with the binding of fluorescein isothiocanate-triflavin to the glycoprotein (GP)IIb/IIIa complex in platelets stimulated by collagen. Magnesium sulphate (1.5 and 3.0 mmol/l) also inhibited phosphoinositide breakdown and intracellular Ca+2 mobilization in human platelets stimulated by collagen. Magnesium sulphate (3.0 mmol/l) significantly inhibited thromboxane A2 formation stimulated by collagen in platelets. Moreover, magnesium sulphate (1.5 and 3.0 mmol/l) obviously increased the fluorescence of platelet membranes tagged with diphenylhexatriene. In addition, magnesium sulphate (1.5 and 3.0 mmol/l) increased the formation of cyclic adenosine monophosphate (AMP) in platelets. Phosphorylation of a protein of Mr 47 000 (P47) was markedly inhibited by magnesium sulphate (1.5 mmol/l). In conclusion, the antiplatelet activity of magnesium sulphate may involve the following two pathways. (1) Magnesium sulphate may initially induce membrane fluidity changes with resulting interference of fibrinogen binding to the GPIIb/IIIa complex, followed by inhibition of phosphoinositide breakdown and thromboxane A2 formation, thereby leading to inhibition of both intracellular Ca2+ mobilization and phosphorylation of P47. (2) Magnesium sulphate might also trigger the formation of cyclic AM, ultimately resulting in inhibition of the phosphorylation of P47 and intracellular Ca+2 mobilization.
------>tmu_sno=None
------>sno=6666
------>authors2=None
------>authors3=None
------>authors4=None
------>authors5=None
------>authors6=None
------>authors6_c=None
------>authors=Sheu JR, Hsiao G, Shen MY, Fong TH, Chen YW, Lin CH, Chou DS
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=None
------>publish_area=None
------>updateTitle=Mechanisms involved in the antiplatelet activity of magnesium in human platelets.
------>language=2
------>check_flag=
------>submit_date=
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=
------>publish_year=2002
------>submit_flag=
------>publish_month=None
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z